Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antiretroviral therapy (ART) combined with interleukin-2 (IL-2) is a therapeutic approach for HIV infection. ART works by suppressing HIV viral replication, while IL-2 is a cytokine that regulates the proliferation and differentiation of lymphocytes. When used together, this combination has been shown to induce greater expansion of CD4 T cells than antiretroviral drugs alone. IL-2 is typically administered in cycles, either subcutaneously or intravenously, alongside continuous ART. While the combination significantly increases CD4 cell counts, clinical trials have not demonstrated improvements in important clinical outcomes such as reduced mortality or opportunistic infections compared to ART alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antiretroviral therapy + interleukin-2.